198 related articles for article (PubMed ID: 38073310)
21. Novel immunotherapy strategies for treatment of neuroendocrine neoplasms.
Al-Toubah T; Cives M; Strosberg J
Transl Gastroenterol Hepatol; 2020; 5():54. PubMed ID: 33073049
[TBL] [Abstract][Full Text] [Related]
22. A comprehensive validation of the novel 8th edition of American Joint Committee on Cancer staging manual for the long-term survivals of patients with non-functional pancreatic neuroendocrine neoplasms.
Yang M; Zeng L; Yao WQ; Ke NW; Tan CL; Tian BL; Liu XB; Xiang B; Zhang Y
Medicine (Baltimore); 2020 Nov; 99(46):e22291. PubMed ID: 33181635
[TBL] [Abstract][Full Text] [Related]
23. mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs).
Zanini S; Renzi S; Giovinazzo F; Bermano G
Front Endocrinol (Lausanne); 2020; 11():562505. PubMed ID: 33304317
[TBL] [Abstract][Full Text] [Related]
24. Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas.
Tang LH; Untch BR; Reidy DL; O'Reilly E; Dhall D; Jih L; Basturk O; Allen PJ; Klimstra DS
Clin Cancer Res; 2016 Feb; 22(4):1011-7. PubMed ID: 26482044
[TBL] [Abstract][Full Text] [Related]
25. New frontiers in imaging including radiomics updates for pancreatic neuroendocrine neoplasms.
Saleh M; Bhosale PR; Yano M; Itani M; Elsayes AK; Halperin D; Bergsland EK; Morani AC
Abdom Radiol (NY); 2022 Sep; 47(9):3078-3100. PubMed ID: 33095312
[TBL] [Abstract][Full Text] [Related]
26. Sporadic non-functioning pancreatic neuroendocrine tumours: multicentre analysis.
Ricci C; Partelli S; Landoni L; Rinzivillo M; Ingaldi C; Andreasi V; Nessi C; Muffatti F; Fontana M; Tamburrino D; Deiro G; Alberici L; Campana D; Panzuto F; Bassi C; Falconi M; Casadei R
Br J Surg; 2021 Jul; 108(7):811-816. PubMed ID: 33724300
[TBL] [Abstract][Full Text] [Related]
27. The landscape of molecular alterations in pancreatic and small intestinal neuroendocrine tumours.
Scarpa A
Ann Endocrinol (Paris); 2019 Jun; 80(3):153-158. PubMed ID: 31072588
[TBL] [Abstract][Full Text] [Related]
28. Gastroenteropancreatic neuroendocrine neoplasms: genes, therapies and models.
Kawasaki K; Fujii M; Sato T
Dis Model Mech; 2018 Feb; 11(2):. PubMed ID: 29590641
[TBL] [Abstract][Full Text] [Related]
29. Open issues on G3 neuroendocrine neoplasms: back to the future.
Zatelli MC; Guadagno E; Messina E; Lo Calzo F; Faggiano A; Colao A;
Endocr Relat Cancer; 2018 Jun; 25(6):R375-R384. PubMed ID: 29669844
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs).
Puccini A; Poorman K; Salem ME; Soldato D; Seeber A; Goldberg RM; Shields AF; Xiu J; Battaglin F; Berger MD; Tokunaga R; Naseem M; Barzi A; Iqbal S; Zhang W; Soni S; Hwang JJ; Philip PA; Sciallero S; Korn WM; Marshall JL; Lenz HJ
Clin Cancer Res; 2020 Nov; 26(22):5943-5951. PubMed ID: 32883742
[TBL] [Abstract][Full Text] [Related]
31. A Subset of Large Cell Neuroendocrine Carcinomas in the Gastroenteropancreatic Tract May Evolve from Pre-existing Well-Differentiated Neuroendocrine Tumors.
Pelosi G; Bianchi F; Dama E; Metovic J; Barella M; Sonzogni A; Albini A; Papotti M; Gong Y; Vijayvergia N
Endocr Pathol; 2021 Sep; 32(3):396-407. PubMed ID: 33433886
[TBL] [Abstract][Full Text] [Related]
32. APOBEC3B High Expression in Gastroenteropancreatic Neuroendocrine Neoplasms and Association With Lymph Metastasis.
Feng C; Zheng Q; Yang Y; Xu M; Lian Y; Huang J; Jiang Y
Appl Immunohistochem Mol Morphol; 2019 Sep; 27(8):599-605. PubMed ID: 30095460
[TBL] [Abstract][Full Text] [Related]
33. Alterations in Ki67 Labeling Following Treatment of Poorly Differentiated Neuroendocrine Carcinomas: A Potential Diagnostic Pitfall.
Vyas M; Tang LH; Rekhtman N; Klimstra DS
Am J Surg Pathol; 2021 Jan; 45(1):25-34. PubMed ID: 33177340
[TBL] [Abstract][Full Text] [Related]
34. [Neuroendocrine neoplasms : Two families with distinct features unified in one classification (German version)].
Klöppel G
Pathologe; 2019 May; 40(3):211-219. PubMed ID: 30969346
[TBL] [Abstract][Full Text] [Related]
35. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.
Fazio N; Milione M
Cancer Treat Rev; 2016 Nov; 50():61-67. PubMed ID: 27636009
[TBL] [Abstract][Full Text] [Related]
36. Genomic Profiles and Current Therapeutic Agents in Neuroendocrine Neoplasms.
Ohmoto A; Morizane C
Curr Drug Targets; 2020; 21(4):389-405. PubMed ID: 31633473
[TBL] [Abstract][Full Text] [Related]
37. Epidemiological analysis of lung and mediastinal neuroendocrine neoplasms in Japan based on the national database.
Matsuoka S; Koizumi T; Otsuki K; Tanaka Y; Kanda S; Ide S; Mishima S; Takeda T; Miura K; Eguchi T; Hamanaka K; Shimizu K
Cancer Epidemiol; 2022 Apr; 77():102116. PubMed ID: 35144127
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy and potential predictive biomarkers in the treatment of neuroendocrine neoplasia.
Xu G; Wang Y; Zhang H; She X; Yang J
Future Oncol; 2021 Mar; 17(9):1069-1081. PubMed ID: 33136448
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapy in Neuroendocrine Neoplasms: Where Are We Now?
Fazio N; Abdel-Rahman O
Curr Treat Options Oncol; 2021 Feb; 22(3):19. PubMed ID: 33559013
[TBL] [Abstract][Full Text] [Related]
40. Molecular profile of pancreatic neuroendocrine neoplasms (PanNENs): Opportunities for personalized therapies.
Arakelyan J; Zohrabyan D; Philip PA
Cancer; 2021 Feb; 127(3):345-353. PubMed ID: 33270905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
